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Abstract
Introduction Because of the small size of in situ mammary
cancers in mouse models, high-resolution imaging techniques
are required to effectively observe how lesions develop, grow
and progress over time. The purpose of this study was to use
magnetic resonance (MR) imaging to track in vivo the transition
from in situ neoplasia to invasive cancer in a transgenic mouse
model of human cancer.
Methods MR images of 12 female C3(1) SV40 Tag mice that
develop mammary intraepithelial neoplasia (MIN) were obtained.
MIN is believed to be similar to human ductal carcinoma in situ
(DCIS) and is considered a precursor of invasive tumors. Images
were serially obtained from 10-21 weeks of age at 2-3 week
intervals. MIN lesions were identified based on their morphology
on MR images. Lesions were followed over time and several
lesion features were measured including volume, growth rate
and morphology. For those MIN lesions that progressed to
invasive cancer the progression time was measured.
Results Overall, 21 MIN lesions were initially detected at an
average initial volume of 0.3 ± 0.2 mm3 with an average growth
rate of -0.15 ± 0.66 week-1. Even though all mice were inbred to
express the SV40 Tag transgene in the mammary epithelium and
expected to develop invasive carcinoma, the individual MIN
lesions took vastly different progression paths: (i) 9 lesions
progressed to invasive tumors with an average progression time
of 4.6 ± 1.9 weeks; (ii) 2 lesions regressed, i.e., were not
detected on future images; and (iii) 5 were stable for over 8
weeks, and were demonstrated by a statistical model to
represent indolent disease.
Conclusions To our knowledge, the results reported here are
the first measurements of the timescale and characteristics of
progression from in situ neoplasia to invasive carcinoma and
provide image-based evidence that DCIS may be a non-obligate
precursor lesion with highly variable outcomes. In addition, this
study represents a first step towards developing methods of
image acquisition for identifying radiological characteristics that
might predict which in situ neoplasias will become invasive
cancers and which are unlikely to progress.
Introduction
The processes that characterize and trigger progression of
preinvasive ductal carcinoma in situ (DCIS) to invasive breast
cancer remain elusive. DCIS is a heterogeneous disease in
which neoplastic cells are confined by the basement mem-
brane of lobuloductal or ductal lumen. Progression to invasive
ductal carcinoma (IDC) is thought to occur by first degradation
of the basement membrane, microinvasion of cancer cells into
the surrounding stroma and growth of a solid tumor. The use
of screening mammography has increased rates of detection
of DCIS [1], which has in turn expanded knowledge about the
biology of these earliest stage breast cancers. However, clini-
cal imaging provides only a snapshot of tumor biology. Basic
characteristics of DCIS development over time (i.e., growth
Az: area under the curve; BI-RADS: Breast Imaging Reporting and Data System; DCIS: Ductal carcinoma in situ; GRE: gradient recalled echo; IDC: 
invasive ductal carcinoma; IDL: Interactive Data Language; MIN: mammary intraepithelial neoplasia; MR: magnetic resonance; PET: positron emission 
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rates and changes in morphology) and progression to IDC are
still largely unknown [2].
Fundamental questions about the natural history of DCIS have
remained unanswered largely because they are difficult to
study in women. Due to obligate surgical excision of newly
diagnosed cancers, subsequent lesion progression cannot be
followed. A few studies have examined the outcome in a small
number of women whose DCIS was initially misdiagnosed as
benign disease, that is, treated by biopsy alone [3,4]. In one
such study, 6 of 13 cases of DCIS progressed to invasive
breast cancer in an average of nine years. In another, 11 of 28
women with misdiagnosed low-grade DCIS developed inva-
sive carcinoma in the same quadrant, the majority within 15
years. These studies and others [5] have prompted some to
suggest that DCIS may be over-diagnosed and over-treated
[6-8] because not all will progress to invasive cancer. If this is
the case, it is clinically important to identify predictive markers
that can distinguish those DCIS that will remain indolent from
those that will progress to life-threatening disease. Some stud-
ies suggest that a higher nuclear grade is related to an aggres-
sive phenotype, because these lesions are more likely to recur
as invasive tumors [9]. Although human studies provide impor-
tant insights into the natural history of DCIS, they usually suffer
from having small patient numbers, having a biased lesion pop-
ulation (i.e., only those DCIS that were initially misdiagnosed),
performing interventions that could alter disease state and
progression (i.e., biopsy or lumpectomy), and focusing on out-
come rather than detailed measurements of lesion morphology
or biology. It is difficult to fully understand DCIS development
or the key steps involved in progression of in situ disease with-
out detailed empirical data directly following DCIS as it devel-
ops and progresses over time.
Transgenic mouse models of human breast cancer provide an
experimental framework with which to begin to understand the
natural history of DCIS. Because of the small size of in situ
mammary neoplasias in mouse models, high-resolution imag-
ing techniques are required to effectively observe how lesions
develop, grow and progress over time. Recently, our labora-
tory reported high-resolution in vivo magnetic resonance (MR)
images of pre-invasive mammary intraepithelial neoplasias
(MIN) in the simian virus 40 large T antigen (SV40 Tag) mouse
model of human breast cancer [10]. This work demonstrated
that both MIN and early invasive cancers could be identified
and accurately classified based on their appearance on MR
imaging, using histological analysis of the same lesions for ver-
ification. In the current study, we used these new MR tech-
niques to follow in situ mammary neoplasias in SV40 Tag mice
over time in individual animals. Specifically, the timescales and
characteristics of the development and progression of in situ
to invasive carcinoma were evaluated, and predictive markers
of invasive progression were explored.
Materials and methods
Animals
All procedures were carried out in accordance with the Univer-
sity of Chicago's Animal Care and Use Committee approval.
The C3(1) SV40 Tag transgenic mouse model of breast can-
cer was used. In this model, expression of SV40 large T anti-
gen is targeted to the mammary gland in females via the C3
promoter. Female mice develop mammary neoplasias that
resemble human intraductal neoplasias, including progression
through atypical ductal hyperplasia (about eight weeks), MIN
[11], which is similar to human DCIS (about 12 weeks), and
invasive tumors (about 16 weeks) [12]. A total of 12 mice were
selected for serial MR imaging. Four of 12 mice were selected
for serial imaging every two weeks from ages 10 to 20 weeks.
Eight of 12 were selected for serial imaging every three weeks
from 12 to 21 weeks. An additional three 15-week-old C3(1)
SV40 mice were selected for reproducibility studies of MR
measurements.
MR imaging experiments
The left inguinal mammary glands were selected for repeat in
vivo  imaging performed with a Bruker 9.4 Tesla magnet
(Bruker-Biospin, Billerica, MA, USA). Axial gradient recalled
echo (GRE) images with fat suppression (repetition time/echo
time = 675/7 ms, field of view = 3.0 × 3.0 cm, matrix size =
256 × 256, number of excitation = 2, number of slices = 42,
slice thickness = 0.5 mm, in-plane resolution = 117 microns
and flip angle = 30°) across the entire sensitive volume of an
open birdcage surface coil were obtained, so that images of
the complete inguinal glands were acquired [10,13]. To facili-
tate spatial correlations between serial MR images, a fine pol-
yethylene mesh about 3.0 cm × 2.0 cm in size with 3.0 mm
spacing was embedded in partially deuterated agar and
wrapped around each mouse. This grid produced a pattern on
MR imaging that was used for registration of serial MR images
so that lesions could be located and followed over time [10].
The grid was wrapped around the mouse during imaging, and
using a Sharpie marker its position was marked on the skin of
the mouse. These marks guided placement of the grid in a sim-
ilar position upon repeat imaging. To assess the reproducibility
of MR measurements, mice (n = 3) were reimaged under dif-
ferent conditions, including altered positioning in the coil, slice
selections and imaging at different times. Animals were anes-
thetized prior to imaging experiments, and anesthesia was
maintained during imaging at 1.5% isoflorane. The tempera-
ture, heart rate and respiration rate were monitored with data
taken every minute, and the respiration rate was used to obtain
gated images.
Lesion identification
In a prior study, we found that MR images acquired with a GRE
pulse sequence demonstrated high sensitivity and specificity
for both MIN and early invasive tumors (Figure 1) [10]. C3(1)
SV40 Tag mice were imaged at various stages of cancer
development and sacrificed afterwards to perform detailedAvailable online http://breast-cancer-research.com/content/11/5/R65
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correlations with histology using an agar grid. Several lesion
features were evaluated, including morphology based on a
simplified version of the Breast Imaging Reporting and Data
System (BI-RADS) lexicon [14] as follows: type (mass or non-
mass), shape/distribution (for mass lesions: round, oval, lobu-
lar or irregular; for nonmass lesions: linear, ductal or
segmental), margins (for mass lesions only: smooth or irregu-
lar) and pattern (for mass lesions: homogeneous or heteroge-
neous; for nonmass lesions: homogeneous, stippled or
clumped). We found that the type descriptors 'mass' and 'non-
mass' were highly specific to invasive tumors and MIN, respec-
tively. The results from our previous studies provided the basis
for the present work by demonstrating that: (i) all MR findings
in the gland correspond to MIN or invasive cancer, that is,
there are no false positives; (ii) MIN, early invasive tumors and
lymph nodes can be reliably identified based on morphology;
and (iii) an agar grid can be used to localize and follow lesions
over time. This work also demonstrated that image-based
assessments of disease stage (i.e., in situ vs. invasive) are
highly suggestive of true histology, but do not constitute defin-
itive evidence thereof.
Analysis of lesion features and development
All image analysis was performed using software written in
Interactive Data Language (IDL) (Research Systems, Inc.,
Boulder, CO, USA). The images of mouse mammary glands
were analyzed in a manner analogous to methods used when
evaluating human breast images. In women, cancers are often
assigned a location by dividing the breast in quadrants relative
to the nipple: upper-outer, upper-inner, lower-outer and lower-
inner. Cancers within a quadrant are usually grouped as one,
and the worst pathology determines the overall diagnosis; in
other words, an invasive cancer with nearby extensive DCIS is
considered an invasive tumor. For the mice, we proceeded
with a similar analysis (Figure 2). The inguinal mammary glands
were divided into three regions, this time using the intramam-
mary lymph node as a reference point. Regions were examined
to identify all ducts with MIN and invasive tumors, using the
morphologic classification of lesion type (as defined above).
Lesions within each region were grouped together (if neces-
sary) and the following features were then evaluated: age at
initial lesion detection (weeks), volume (mm3), further morpho-
logic classification (as above, shape/distribution, margins and
pattern) and distance from the intramammary lymph node
(mm).
Using the agar grid and lesion location relative to the
intramammary lymph node, lesion development was followed
over time. This could only be assessed in cases where the
lesion had been imaged at least twice. Growth rate was calcu-
lated according to the following equation:
- where V is lesion volume (mm3), t is the time in weeks, and α
is the growth rate (per week). This was calculated separately
for MIN (αMIN) and invasive tumors (αtumor). Changes in mor-
phology as lesions developed were also examined separately
for in situ and invasive tumors.
Vt Vet () , = 0
α (1)
Figure 1
In vivo axial gradient recalled echo MR images and corresponding H&E-stained sections from a prior study [10] In vivo axial gradient recalled echo MR images and corresponding H&E-stained sections from a prior study [10]. The magnetic resonance (MR) 
images and H&E-stained sections represent different orientations, as each MR image represents only one cross-sectional slice through the mam-
mary gland while the histologic sections show the entire gland. During imaging, the mammary glands are attached to the skin of the mouse, and are 
therefore wrapped around the body of the mouse. For excision, the glands are peeled back from the body of the mouse and laid flat, so that coronal 
H&E-stained sections can be obtained. We used an agar grid (a polyethylene mesh embedded in partially deuterated agar) to register the axial MR 
images with the H&E-stained sections. (a) Normal mammary gland, with intramammary lymph node, (b) lymph node and mammary intraepithelial neo-
plasia (MIN), (c) lymph node and small tumor. For each MR image, the display field of view is approximately 2.0 × 2.0 cm, and in-plane resolution is 
117 microns.Breast Cancer Research    Vol 11 No 5    Jansen et al.
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Reproducibility of MR assessments of lesions type (as 'non-
mass' or 'mass'), morphology descriptors and size was evalu-
ated for three mice with imaging repeated under different
conditions.
Analysis of MIN progression into invasive cancer
Each MIN was followed over time to determine whether inva-
sive cancer developed in that region in the future. Specifically,
if any invasive tumor developed in the same region on subse-
quent images, the lesion was classified as having progressed
and the progression time Tprog (in weeks) was calculated: Tprog
= age at initial detection of invasive tumor - age at initial detec-
tion of MIN. The average progression time μprog and the stand-
ard deviation of progression times σprog were then calculated.
If an invasive tumor was not found in subsequent images, the
latency time Tlat (in weeks) was determined: Tlat = age at final
imaging session - age at initial detection of MIN. To determine
whether some latent lesions truly represented non-progress-
ing or 'indolent' disease, a threshold T0 was found so that MIN
lesions with Tlat > T0 could be considered a biologically distinct
class of 'indolent' lesion. Details of the statistical method used
are in the following section. In addition, the prior images of all
invasive tumors were evaluated to determine how many were
preceded by MIN.
We tested if a larger volume, earlier age at initial detection and
a larger growth rate (αMIN) were predictors of whether that MIN
lesion would progress in the future to an invasive tumor. In
addition, to test whether cancer progression is related to
lesion location in the gland, the distance from the lymph node
was also evaluated as a predictor. The average value of each
of these parameters was calculated separately in both pro-
gressing and indolent MIN, and compared using the Student's
t-test. Receiver operating curve (ROC) analysis (ROCKIT
0.9B Beta Version, Charles E. Metz, University of Chicago, IL,
USA) was performed to determine the diagnostic accuracy for
each parameter in the task of distinguishing progression from
indolent MIN. For each parameter, ROC analysis yielded area
under the curve (Az) values that quantified diagnostic accu-
racy.
Statistical method for identifying indolent MIN
We consider two groups of MIN: (i) lesions in which progres-
sion to invasive cancer was observed, with average time to
progression Tprog = μprog ± σprog; and (ii) lesions in which pro-
gression to invasive cancer was not observed, with a range of
latency times Tlat. Our goal is to determine which lesions in the
second group, if any, truly represent non-progressing or indo-
lent disease. We begin first with the population of MIN lesions
in which progression to invasive cancer was observed. We
assume the progression time Tprog for each lesion is normally
distributed N(μprog, σprog), and denote Nprog as the number of
lesions in the progressing group. We next consider a subset
of the latent MIN lesions with latency times Tlat longer than a
threshold T0, and denote N0 the number of lesions with Tlat >
T0. The probability that after randomly drawing n = Nprog+ N0
lesions from N(μprog, σprog), we have selected at most Nprog
lesions with Tprog < T0 can be found using cumulative form of
the binomial distribution, given by the following density func-
tion:
Pk
n
k
pp kn k () ( ) , =
⎛
⎝
⎜
⎞
⎠
⎟ − − 1 (2)
Figure 2
Flowchart demonstrating method for analyzing inguinal mammary glands for early murine mammary cancer Flowchart demonstrating method for analyzing inguinal mammary glands for early murine mammary cancer. MIN = mammary intraepithelial neoplasia.Available online http://breast-cancer-research.com/content/11/5/R65
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- where p is the probability that one progressing lesion can
have Tprog < T0 (can be calculated using the cumulative distri-
bution function of the normal distribution) and k = Nprog. Thus,
for each T0 we obtain a probability that lesions with Tlat > T0 are
part of the progressing group.
Results
Lesion features and development
Overall, 2 of 12 mice did not develop any cancerous lesion in
the imaged inguinal glands. In the remaining 10 mice, a total of
21 MIN lesions developed. In eight of these mice a total of 14
invasive tumors developed (not always preceded by MIN in the
same region). The lesion features at initial detection are sum-
marized in Table 1. Most MIN lesions developed in the mid
(10/21) or lower (9/21) gland regions, at a mean (± standard
deviation) age of 12.7 ± 2.6 weeks and an average initial vol-
ume of 0.34 ± 0.22 mm3. MIN typically presented in a ductal
or segmental shape and a homogenous pattern. Invasive
tumors also developed predominantly in the mid (8/14) or
lower (5/14) gland region. Tumors appeared at an average
age of 16.3 ± 3.2 weeks at an initial volume at the time of
detection of 17.2 ± 41.6 mm3. The latter value was skewed
due to two tumors that presented initially at a very large volume
(>120 mm3); excluding these two very large tumors reduced
the average initial tumor volume to 1.96 ± 2.01 mm3. Both of
the very rapidly growing large tumors were observed to have
developed only three weeks after the in situ phase in the same
animal. The typical invasive tumor morphology at initial detec-
tion was a round shape with smooth margins and a homoge-
neous pattern.
The subsequent development of MIN was studied in those 15
of 21 lesions in nine mice that were detected and classified as
MIN at least twice by MRI. Interestingly, the average growth
Table 1
The features at initial detection of MIN and early invasive cancers
Feature at initial detection MIN
(n = 21)
Invasive cancers
(n = 14)
Region Upper gland 2 (9%) 1 (7%)
Mid gland 10 (48%) 8 (57%)
Lower gland 9 (43%) 5 (36%)
Distance from
lymph node (mm)
3.5 ± 1.8 6.6 ± 7.6
Age (weeks) 12.7 ± 2.6 16.3 ± 3.2
Volume (mm3) 0.34 ± 0.22 17.2 ± 41.6*
Morphology
Type** Nonmass 21 (100%) 0 (0%)
Mass 0 (0%) 14 (100%)
Distribution (Nonmass) Ductal 11 (52%) --
Segmental 9 (43%) --
Linear 1 (5%) --
Pattern (Nonmass) Clumped 2 (10%) --
Homogeneous 14 (67%) --
Stippled 5 (23%) --
Shape (Mass) Irregular -- 3 (21%)
Round -- 9 (64%)
Lobular -- 2 (14%)
Margins (Mass) Smooth -- 10 (71%)
Irregular -- 4 (29%)
Pattern (Mass) Heterogeneous -- 4 (29%)
Homogeneous -- 10 (71%)
*If we exclude two tumors that initially presented at over 100 mm3, the average was 1.96 ± 2.01 mm3.
** Please note that by definition 'mass' lesions were classified as invasive tumors, while 'nonmass' lesions were classified as mammary 
intraepithelial neoplasia (MIN).Breast Cancer Research    Vol 11 No 5    Jansen et al.
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rate was slightly negative αMIN = -0.15 ± 0.66 weeks. Several
lesions exhibited close to zero growth (Figure 3); two in partic-
ular exhibited considerably negative growth because on sub-
sequent imaging they were no longer detected (Figure 4a).
This could be evidence of in situ cancer disappearance; at the
least, it indicates the lesion has substantially reduced in size,
that is, it had regressed. Some of the MIN lesions also exhib-
ited morphological changes as they developed. Two of 15
lesions exhibited a change in lesion shape from ductal to seg-
mental. More significantly, 8 of 15 lesions showed changes in
lesion pattern from homogeneous to clumped or stippled.
Early invasive tumors exhibited less variability compared with
MIN as they grew over time. For the 8 of 14 invasive tumors
that were imaged at least twice, the average growth rate was
0.53 ± 0.38 weeks, significantly higher than that of MIN (P =
0.003). Although the growth rates of invasive tumors varied
considerably (Figure 3), none of the invasive cancers reduced
in size over time. Furthermore, tumors maintained similar mor-
phologic characteristics as they developed. Only two of eight
tumors changed morphology over time: one transitioned from
a round to lobular shape, and the other from a round mass with
smooth margins to an irregular mass with irregular margins.
This suggests that the growth patterns of early invasive tumors
are more stable than MIN lesions.
In preliminary reproducibility experiments, we found that the
classification of lesion type as 'mass' or 'nonmass' is robust
and does not change with different setups. In addition, meas-
urements of early invasive tumor morphology and size were
reproducible. For 'nonmass' lesions, however, morphologic
descriptors of distribution and pattern were not consistent on
repeat imaging.
Progression of MIN into early invasive cancers
With the caveat that image-based assessments of lesion his-
tology (i.e., in situ vs. invasive) are highly predictive but not
conclusive proof of true disease stage, we proceeded to use
image-based features to analyze in situ neoplastic progres-
sion. Based on image-based evidence alone, nine of 21 MIN
lesions progressed into invasive cancers with an average pro-
gression time of Tprog = 4.6 ± 1.9 weeks (Figure 4b). Of these,
five MIN lesions progressed to invasive cancer in two to three
weeks, three within six to seven weeks, and one in eight to ten
weeks. Eleven of 21 MIN did not progress to invasive tumors
with an average latency time of Tlat = 5.8 ± 3.8 weeks (Figure
4c). Of these, four did not progress for at least two to three
weeks, two for at least six to seven weeks and five were stable
for at least eight to ten weeks (i.e., Tlat ≥ 8 weeks). One of 21
MIN developed at the last imaging time point (21 weeks of
age) and thus subsequent development was unknown. Nine of
14 invasive tumors were preceded by MIN that was detected
by MR imaging; MIN was not detected in the prior images of
four tumors, and one tumor was detected at the first imaging
session (age 12 weeks) and thus prior history was unknown.
We compared the growth rates of those MIN lesions that pro-
gressed to invasive cancer to the growth rates of the invasive
tumors that subsequently developed in the same region. This
was possible in six of the nine MIN lesions that progressed to
invasive cancer. There was a tendency for increased MIN
growth rate to be correlated with an increased growth rate of
the subsequent invasive cancer; for the three MIN lesions with
the lowest growth rates (average αMIN = -0.06 ± 0.07 per
week) the invasive tumors that developed in the same region
had an average invasive growth rate of αtumor = 0.36 ± 0.38
per week. In comparison, for the three MIN lesions with the
Figure 3
Scatter plot of growth rates and lesion volume at initial detection in nine mice: 15 MIN lesions (in nine mice) and eight invasive tumors (in seven  mice) Scatter plot of growth rates and lesion volume at initial detection in nine mice: 15 MIN lesions (in nine mice) and eight invasive tumors (in seven 
mice). Note that this plot displays only those lesions in which a growth rate could be calculated, i.e., that were imaged at least twice as mammary 
intraepithelial neoplasia (MIN) or invasive tumor. Six of the MIN and invasive tumor data points (in six mice) represent growth rates of progressing 
MIN lesions and the invasive phase, subsequently found in the same region of the mammary gland.Available online http://breast-cancer-research.com/content/11/5/R65
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highest growth rate (average αMIN = 0.31 ± 0.25 per week) the
invasive tumors that developed in the same region had a
higher average growth rate of αtumor = 0.83 ± 0.37 per week,
although this difference was not significant (P = 0.19).
Using the statistical method outlined in the Methods, and with
Nprog = 9, μprog = 4.56 and σprog = 1.9 weeks, we found that
there was a less than 0.5% probability that lesions with Tlat
greater than or equal to eight weeks could be from the same
population as progressing MIN. In other words, according to
our methods, MIN lesions with Tlat of eight weeks or more rep-
resented indolent disease that is biologically different from the
MIN lesions that progress.
There was a trend for indolent MIN lesions to develop earlier
than lesions that went on to progress to invasive cancer, to be
closer to the lymph node and to have a lower growth rate com-
pared with progressive MIN (Table 2). However, due to the
small sample size, the confidence intervals of the Az values
were large.
Discussion
We have used serial MR imaging to study the natural history of
in situ neoplasia in a transgenic model of human breast can-
cer. The timescales of neoplastic initiation and progression to
invasive cancer in C3(1) SV40 Tag mice that can only be
derived from repeated non-invasive imaging were measured.
Significantly, we found that even in these mice that are genet-
ically predisposed to develop invasive carcinoma, a substantial
proportion of in situ cancers did not progress to invasive
tumors within 21 weeks of monitoring. To our knowledge,
these results provide the first detailed, high-resolution meas-
urements of early mammary cancer natural history in mice. Our
work complements work by Abbey and colleagues that inves-
tigated malignant transformation of in situ mammary cancer in
a transplantable tissue model, using positron emission tomog-
raphy (PET) to provide metabolic characterization at lower
Figure 4
Examples of MIN progression in three different mice Examples of MIN progression in three different mice. (a) An example of possible mammary intraepithelial neoplasia (MIN) regression. MIN is vis-
ible at 12 weeks of age (left) beside lymph node, but cannot be found six weeks later anywhere near the lymph node. Here, only one slice is shown 
demonstrating absence of a lesion near the lymph node (right). (b) MIN is first detected early on at 10 weeks of age, and in this axial MR image 
appears in cross section. The duct grew more distended at 12 and 14 weeks, and by 16 weeks had become an invasive tumor. The tumor then con-
tinued to grow and by 20 weeks was quite large. Interestingly, at 20 weeks it appeared that new MIN had developed close to the tumor. (c) MIN has 
developed at 10 weeks and does not progress to invasive cancer. Field of view for all images is 3.0 × 2.0 cm, and in-plane resolution is 117 microns.Breast Cancer Research    Vol 11 No 5    Jansen et al.
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spatial resolution (5 mm3 voxel size compared with 0.0068
mm3 in our study) [15,16].
In the present study, we measured changes in image-based
features that are highly predictive of disease stage. As this was
a serial imaging study, we could not perform histologic confir-
mation of the image-based findings. This underscores a signif-
icant challenge with noninvasive imaging of disease
progression: it is very difficult to determine lesion histology
without sacrificing the animal, thereby losing longitudinal infor-
mation. With larger and more detailed sensitivity/specificity
studies that correlate image-based features with a wide variety
of histologic presentations, this limitation can be mitigated.
If image-based measurements are to be robust predictors of
disease stage, their reproducibility must be established. Our
preliminary work suggests that assessment of in situ vs. inva-
sive disease (via determination of lesion type) is reproducible,
as are measurements related to size and morphology of early
invasive tumors. However, in situ lesion morphology (i.e., dis-
tribution or pattern) may not be adequately reproducible. Fur-
ther studies are needed to quantify reproducibility of MR
measurements of early murine mammary cancer.
The C3(1) SV40 Tag mouse model is being used for a wide
variety of studies, ranging from evaluating effects of interven-
tional and preventive therapies [17-30], to understanding
molecular and genetic alterations occurring at various stages
of disease progression [31-36]. Our results contribute new
observations regarding this mouse model of breast cancer.
MIN lesions grow slowly on average, and can both progress to
invasive tumors or remain indolent, as has been suggested to
be true for DCIS in women [2-4]. This is consistent with addi-
tional stochastic mutations taking place as secondary transfor-
mation events beyond expression of Tag as required for
cancer progression in this model [33]. We have also found evi-
dence for in situ cancer regression, which if validated in larger
numbers with detailed pathology correlation, would be direct
demonstration of spontaneous breast cancer regression [37-
39]. The heterogeneity of progression paths demonstrates
that the C3(1) SV40 mouse model may be a good candidate
for assessing the effect of therapies that delay the progression
of DCIS. Early invasive tumors show less variability in morphol-
ogy as they grow compared with MIN. Although there was a
wide variability of growth rates of early invasive cancers, over-
all they grew much faster than in situ cancers, and none
decreased in size or regressed. There was a trend for
increased MIN growth rate to be a predictor of both the even-
tual development of invasive carcinoma, and a higher invasive
tumor growth rate, in the same region. Unfortunately, in this
pilot study the number of cases was too small to draw conclu-
sions with statistical significance.
It is important to note that our results pertain to this specific
mouse model; it will be important to establish imaging tech-
niques and assess similar characteristics in other mouse mod-
els of human breast cancer. If some features can be found that
persist across mouse models, they may ultimately demon-
strate applicability to human disease.
The natural history of breast cancer is still an open question,
and there are many theories of the mechanisms governing the
growth and progression of early breast cancers in women. The
'angiogenic switch' is thought to be a crucial step during
breast tumorigenesis, and has been hypothesized to occur at
or before the in situ stage [40]. Franks and colleagues have
used non-linear mathematical models to predict that invasion
will occur at the middle of ducts distended by DCIS due to
increased mechanical pressure [41-43]. Tabar and colleagues
suggest that true in situ lesions in fact originate in lobules, and
that a separate more aggressive disease representing a duct-
forming invasive carcinoma is being incorrectly included with
other in situ cancers [44,45]. Due to an absence of empirical
data of the detailed morphologic changes and other changes
that occur during progression of in situ cancers, such theories
may be difficult to evaluate. Our work and extensions thereof,
for example the use of dynamic contrast-enhanced MR imag-
ing to probe changes in vasculature, can provide detailed and
direct measurements of tumorigenesis on which these mathe-
matical and physiologic models of disease initiation and pro-
gression can be evaluated.
There are several limitations to this study. First, lesion morphol-
ogy was assessed using 2D axial slices rather than a 3D ren-
Table 2
Values of lesion features in progressing vs. indolent MIN
Feature Progressing MIN (n = 9) Indolent MIN (n = 5) P value Az
Age at first detection (weeks) 12.3 ± 2.3 10.6 ± 0.9 0.07 0.83 (0.51 to 0.97)
Maximum volume (mm3) 0.55 ± 0.66 0.67 ± 0.87 0.81 0.48 (0.19 to 0.78)
Growth rate (per week)** 0.21 ± 0.29 -0.66 ± 0.952 0.11 0.83 (0.45 to 0.98)
Distance from lymph node (mm) 4.2 ± 2.2 2.7 ± 1.6 0.18 0.75 (0.43 to 0.94)
** Student t-test comparisons yielded P values shown above. For the area under the curve (Az) values, numbers in parentheses represent 95% 
confidence intervals.
Growth rate could only be measured for those lesions that were imaged as mammary intraepithelial neoplasia (MIN) at least twice.Available online http://breast-cancer-research.com/content/11/5/R65
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dering of the inguinal glands. This could compromise the
assessment of lesion morphology, particularly of MIN located
in the lower gland area.
Second, there may have been some errors in lesion identifica-
tion. Although the descriptors of 'nonmass' and 'mass' are
highly specific to MIN and invasive tumors, respectively, the
'mass' descriptor is not perfectly correlated [10] implying that
some MIN lesions may have been misidentified as invasive
tumors. More generally, in this study it may have been difficult
to distinguish focal MIN from invasive cancer, or to pinpoint the
exact point of transition from MIN to invasion due to the two to
three-week sampling interval. On the other end of the progres-
sion spectrum, distinguishing MIN from benign conditions,
such as atypical ductal hyperplasia or epithelial proliferative
diseases, may be a challenging task in mice as it is in women.
A much larger sensitivity/specificity study will be required to
better correlate a wider variety of image-based features with
histology, in order to minimize such confusion so that disease
stage can be assessed with increased confidence. Similarly,
MR imaging of nontransgenic normal mice should be per-
formed to document the presentation of normal murine mam-
mary gland anatomy, upon which findings in transgenic
models can be compared.
Third, the numbers of lesions studied was rather small, limiting
the statistical significance of our findings. To address this,
both an increased number of mice should be imaged as well
as an increased number of mammary glands in each mouse
(rather than only the inguinal glands on one side). In this way,
cancer development can be assessed in the whole mouse,
and data can be analyzed to determine whether lesions in the
same animal can be considered as independent.
Fourth, in this study we did not consistently perform end-point
histologic evaluation of imaged mammary glands.
Fifth, mice were followed to 20 or 21 weeks of age rather than
until natural death, so that studies of cancer progression could
not be performed past this age. Although the range of cancer
development in this model spans 10 to 24 weeks of age, and
most female mice must be sacrificed at this time due to
increased tumor burden in the mammary glands, additional
time points should be acquired to definitively assess in situ
cancer progression.
Sixth, changes in the parenchyma that preceded the develop-
ment of MIN could not be easily observed because of the poor
signal-to-noise ratio of the normal tissue. Recent improve-
ments in imaging methods have provided greatly enhanced
images of normal parenchyma, opening up the possibility of
studying changes in the normal mammary glandular tissue that
are precursors to cancer development.
Finally, the new framework we have presented for analyzing
early carcinogenesis in mice may need improvement. For
example, the number of MIN lesions that progressed to inva-
sive tumors may have been over-estimated. Our criterion was
only that an invasive tumor appeared in the same region on
subsequent imaging; however, this tumor may have been inde-
pendent of the original MIN detected previously. The transition
from MIN to invasive tumors was rarely observed directly. In
addition, cancer growth rates could only be calculated for
lesions imaged at least twice, that is, 15 of 21 MIN and 8 of
14 invasive tumors. The remaining lesions were excluded from
any analysis of growth rates, which may have introduced a
bias. These two limitations could be addressed by conducting
serial imaging at higher frequency (i.e., every few days) so that
each MIN lesion can be definitively linked with its subsequent
invasive phase, and so that growth rates can be measured for
all. Lastly, the statistical model we used to identify indolent
lesions could most likely be improved or modified.
In prior work, we introduced MR imaging methods for imaging
early murine mammary neoplasias and invasive cancers, and
subsequently reported on how those techniques could be
used to better interpret clinical MR imaging of the breast [46].
Here, we have established a new role for MR imaging in pre-
clinical studies of the natural history of early breast cancer. In
future work, we plan on performing more detailed studies of
carcinogenesis, by imaging more frequently and at higher res-
olution. In addition, we will explore additional MR imaging tech-
niques, such as dynamic contrast enhanced MR imaging,
diffusion weighted imaging and high spectral-spatial resolu-
tion imaging, to probe the changes in vasculature and cellular-
ity that occur during progression to invasive cancer. Finally,
molecular imaging and gene/protein expression studies will be
explored in conjunction with MRI to interrogate the molecular
mechanisms involved in cancer initiation and progression.
Conclusions
We have used longitudinal noninvasive imaging to gain new
insights into the natural history of early mammary cancer in the
C3(1) SV40 Tag mouse model of human breast cancer. We
found image-based evidence that some in situ mammary can-
cers did not progress to invasive cancers, and investigated
potential predictive markers of progression. This pilot study
represents a first step towards detailed studies of functional
and morphologic characteristics of mammary tumorigenesis,
and developing methods for image acquisition and analysis
that can predict which in situ cancers will become invasive
and which would not. Such investigations would have an
important impact on clinical management of patients with
DCIS.
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